KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041807 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Dongyu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China. Hauptthemen laut MEDLINE: Kinesins, Lung Neoplasms, Adenocarcinoma of Lung, Gene Regulatory Networks. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Founda- tion of China, National Natural Science Foundation of China, CQMU Program for Youth Innovation Team in Future Medicine.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need to identify novel prognostic biomarkers and therapeutic targets. Kinesin Family Member 18B (KIF18B) is implicated in mitosis, yet its precise role in LUAD pathogenesis remains poorly defined. This study investigates the oncogenic and therapeutic role of KIF18B in LUAD. Integrated analysis of The Cancer Genome Atlas Program (TCGA) and Gene Expression Omnibus (GEO) datasets revealed that KIF18B is significantly upregulated in LUAD tissues, with its elevated expression strongly associated with an advanced pathological stage, high grade, and poor patient survival. Single-cell sequencing data analysis further indicated that KIF18B expression in LUAD is closely linked to key malignant processes, including cell cycle progression, proliferation, migration, and epithelial–mesenchymal transition (EMT). Functional experiments demonstrated that KIF18B knockdown markedly suppressed LUAD cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo. Mechanistically, transcriptomic and pathway analyses revealed that KIF18B depletion downregulates Early 2 Factor (E2F) target genes. Luciferase reporter assays confirmed diminished E2F reporter activity as well as E2F2 promoter activity upon KIF18B silencing, while overexpression of E2F1, E2F2, or E2F3 rescued the inhibited proliferative phenotypes induced by KIF18B loss. Collectively, our findings establish KIF18B as an essential driver of LUAD progression that acts through the E2F transcriptional network, nominating it as a promising diagnostic and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China.
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing 400016, China.
ORCID-Profile: Yitao Wang
Förderung
- the National Natural Science Founda- tion of China
- National Natural Science Foundation of China
- CQMU Program for Youth Innovation Team in Future Medicine
Zitieren
APA
Wang, D., Zhang, J., Mi, J., Ding, Z., Xiang, N., Yi, L., Bu, Y., & Wang, Y. (2026). KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041807
Vancouver
Wang D, Zhang J, Mi J, Ding Z, Xiang N, Yi L, et al. KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041807
BibTeX
@article{Wang2026,
author = {Wang, Dongyu and Zhang, Jinlu and Mi, Jinwen and Ding, Zirui and Xiang, Nian and Yi, Lin and Bu, Youquan and Wang, Yitao},
title = {KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041807}
}
EUVIMED